Seven Bridges Genomics (San Francisco) has announced the creation of a subsidiary known as the Unified Patient Network (UPN) to drive clinical research and collaboration between health systems and biopharma companies. The focus of the new subsidiary will be focusing on advancing precision medicine.
The Washington University School of Medicine in St. Louis and the affiliated healthcare organization BJC HealthCare have joined the UPN as founding members.
UPN aims to bring together a group of nonprofit academic health centers and other health systems performing clinical research. UPN will investigate the genetic origins of disease, drawing on a database of de-identified clinical and genomic data.
Seven Bridges genomics has named Dr. David Ledbetter as the chief clinical and research officer of UPN. Ledbetter was formerly the executive vice president and chief scientific officer at Geisinger Health System. He also serves on Seven Bridges’ advisory board.
“The UPN aims to accelerate the scientific advancement and clinical implementation of precision medicine, in a manner that provides truly unprecedented return-of-value to our health system members and their research participants, via clinical whole genome sequencing, genetic screening, genetic counseling, research tools, data assets, collaborative interoperability and a significant incremental funding stream, at no charge to the health systems or patients,” said William Moss, CEO of Seven Bridges and the UPN.
Filed Under: Drug Discovery
